Optinose has developed innovative devices that transform treatment by leveraging the nose for drug delivery in a manner that addresses traditional nasal administration.
Using known molecules, Optinose deepens and broadens tissue penetration, offering the potential to tackle previously intractable challenges, such as delivery across the nose-brain barrier, without deposition to the lung.
Who Should Contact Optinose?
- Pharmaceutical and biotechnology companies interested in evaluating the nasal polyps or migraine applications
- Those seeking an innovative, non-oral, or non-injected delivery platform for their proprietary CNS, systemic, or topical nasal compounds
- Companies seeking to re-evaluate promising compounds that experienced clinical development challenges due to insufficient oral bioavailability, first-pass metabolism, or speed of onset
- Companies seeking to find new or improved uses for existing compounds
The Company offers both single and multi-use intranasal delivery devices for powder and liquid formulations.